Download Full Text (636 KB)
The purpose of this research was to identify the best course of action in response to a diagnosis of unprovoked pulmonary embolism.
•The evidence demonstrates non-inferiority status of new direct oral anticoagulants (DOAC) when indirectly compared to conventional warfarin therapy.
•Aspirin was also found effective in mitigating the risk of recurrence, but to a lesser extent than both DOAC agents and warfarin.
•DOACs are reasonable alternatives to conventional therapy. Attention to individual comorbidities may allow providers to find advantage with one therapy over another.
• The research, thus far, has not been able to identify a universally safe and an effective agent for all patients experiencing a first-time unprovoked pulmonary embolism.
•Additional research is needed to evaluate the duration of therapy and generate more robust data to recommend a specific therapeutic agent for all patients.
Physician Assistant Studies
Date of Work
Pulmonary embolism, warfarin, w direct oral anticoagulants (DOAC), Aspirin
Medicine and Health Sciences
Klucas, Christopher D., "Review of Anticoagulation Therapy in Unprovoked Pulmonary Embolism" (2020). Physician Assistant Scholarly Project Posters. 196.